These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9771059)

  • 1. [Pretreatment with prednisolone enhances the effect of human lymphoblastoid interferon in chronic hepatitis B].
    Krogsgaard K; Marcellin P; Trepo C; Berthelot P; Sanchez-Tapias JM; Bassendine M; Tran A; Ouzan D; Ring-Larsen H; Lindberg J; Enriquez J; Benhamou JP; Bindslev N
    Ugeskr Laeger; 1998 Sep; 160(39):5657-61. PubMed ID: 9771059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group.
    Krogsgaard K; Marcellin P; Trepo C; Berthelot P; Sanchez-Tapias JM; Bassendine M; Tran A; Ouzan D; Ring-Larsen H; Lindberg J; Enriquez J; Benhamou JP; Bindslev N
    J Hepatol; 1996 Dec; 25(6):803-13. PubMed ID: 9007706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B.
    Niederau C; Heintges T; Niederau M; Stremmel W; Strohmeyer G
    Eur J Med; 1992 Nov; 1(7):396-402. PubMed ID: 1341478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone.
    Boxall EH; Sira J; Ballard AL; Davies P; Kelly DA
    J Med Virol; 2006 Jul; 78(7):888-95. PubMed ID: 16721856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High rates of HBsAg loss and seroconversion result from prolonged course of pegasys treatment].
    Li MH; Xie Y; Lu Y; Qiu GH; Liu F; Li XH; Zhao H; Song SJ; Guan XP; Cheng J; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2011 Mar; 19(3):182-5. PubMed ID: 21586235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial.
    Liaw YF; Lin SM; Chen TJ; Chien RN; Sheen IS; Chu CM
    J Hepatol; 1994 Feb; 20(2):175-80. PubMed ID: 8006397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
    Janssen HL; van Zonneveld M; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Niesters HG; Zondervan P; Hansen B; Schalm SW; ;
    Lancet; 2005 Jan 8-14; 365(9454):123-9. PubMed ID: 15639293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial.
    Gregorio GV; Jara P; Hierro L; Diaz C; de la Vega A; Vegnente A; Iorio R; Bortolotti F; Crivellaro C; Zancan L; Daniels H; Portmann B; Mieli-Vergani G
    Hepatology; 1996 Apr; 23(4):700-7. PubMed ID: 8666320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
    de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
    Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan.
    Hsu HY; Tsai HY; Wu TC; Chiang CL; Ni YH; Chen PJ; Chang MH
    Liver Int; 2008 Nov; 28(9):1288-97. PubMed ID: 18397229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
    Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Wu SL; Chang M; Liu RY; Hu LP; Li ZZ; Hua WH; Song SJ; Xie Y
    Chin Med J (Engl); 2017 Mar; 130(5):559-565. PubMed ID: 28229987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
    Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
    J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W; Yuan H; Mao XR; Deng YD; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.